Edition:
United States

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

41.88USD
24 Mar 2017
Change (% chg)

$0.16 (+0.38%)
Prev Close
$41.72
Open
$41.77
Day's High
$42.01
Day's Low
$41.77
Volume
4,558
Avg. Vol
39,144
52-wk High
$54.90
52-wk Low
$41.40

Latest Key Developments (Source: Significant Developments)

Anika Q3 earnings per share $0.59
Wednesday, 26 Oct 2016 04:05pm EDT 

Anika Therapeutics Inc - : Anika reports third quarter 2016 financial results . Q3 earnings per share $0.59 . Q3 revenue $25.8 million versus I/B/E/S view $26.6 million .Q3 earnings per share view $0.47 -- Thomson Reuters I/B/E/S.  Full Article

Anika Q2 earnings per share $0.57
Wednesday, 27 Jul 2016 04:05pm EDT 

Anika Therapeutics Inc : Anika reports second quarter 2016 financial results . Q2 earnings per share $0.57 . Q2 revenue $26.6 million versus I/B/E/S view $24.7 million .Q2 earnings per share view $0.44 -- Thomson Reuters I/B/E/S.  Full Article

Anika Therapeutics announces Canadian launch of cingal
Thursday, 19 May 2016 09:05am EDT 

Anika Therapeutics Inc : Announces Canadian launch of cingal for the treatment of pain associated with osteoarthritis of the knee .Cingal will be marketed and sold in Canada by Pendopharm, a division of Pharmascience Inc, a Quebec-based pharmaceutical company.  Full Article

Anika Therapeutics announces $25 million accelerated share repurchase
Wednesday, 24 Feb 2016 04:10pm EST 

Anika Therapeutics:Will enter into an accelerated share repurchase program to repurchase $25 million of its outstanding common stock.Company will enter into an accelerated stock repurchase agreement with Morgan Stanley & Co. LLC pursuant to a Fixed Dollar Accelerated Share Repurchase Transaction to purchase $25 million of shares of its common stock.  Full Article

Anika Therapeutics Inc announces health canada approval of CINGAL for the treatment of pain associated with osteoarthritis of the knee
Tuesday, 3 Nov 2015 09:00am EST 

Anika Therapeutics Inc:Announces health canada approval of CINGAL for the treatment of pain associated with osteoarthritis of the knee.  Full Article

Anika Therapeutics Inc announces positive results from follow-up study evaluating safety of repeat injection of cingal for treatment of osteoarthritis of knee
Thursday, 9 Jul 2015 08:30am EDT 

Anika Therapeutics Inc:Announces positive results from follow-up study evaluating safety of a repeat injection of cingal for treatment of osteoarthritis of the knee.No statistically significant differences between ae profile of participants in cingal 13-01 study and those in cingal 13-02 study.Says low number of subjects (6.2%) experienced an adverse event (ae) related to the study injection.  Full Article

Anika Therapeutics, Inc. announces strategic collaboration with the institute for applied life sciences (ials) at the university of massachusetts amherst
Wednesday, 17 Jun 2015 08:30am EDT 

Anika Therapeutics, Inc:Says agreement with the Institute for Applied Life Sciences at the University of Massachusetts (UMass) Amherst to collaborate on research to develop a therapy for rheumatoid arthritis.Says Purpose of this research collaboration is to develop a novel modality for the treatment of RA, and if successful, is expected to yield a candidate that will move toward clinical development in 2017.  Full Article

Anika Therapeutics Inc files IDE application with U.S. FDA
Wednesday, 8 Apr 2015 02:30pm EDT 

Anika Therapeutics Inc:Says that it has filed an Investigational Device Exemption (IDE) with the U.S. Food and Drug Administration to conduct a pivotal Phase III clinical trial for Hyalofast, a biodegradable, 3D, HA-based scaffold with autologous bone marrow aspirate concentrate.European clinical data demonstrated that patients who utilized Hyalofast with BMAC in a one-step arthroscopic procedure were able to naturally regenerate hyaline-like cartilage with a minimally invasive and cost-effective procedure.Hyalofast is CE Marked in Europe for the entrapment of mesenchymal stem cells in connection with the treatment of chondral and osteochondral lesions, and it is commercially available in Europe and certain other international markets.  Full Article

More From Around the Web

BRIEF-Anika Therapeutics posts Q4 earnings per share $0.54

* Anika reports fourth quarter and full year 2016 financial results